誉衡药业：2025年净利同比预增50.37%—80.44%

Core Viewpoint - Yuheng Pharmaceutical (002437) expects a net profit attributable to shareholders of 350 million to 420 million yuan for 2025, representing a year-on-year growth of 50.37% to 80.44% [1] Product Performance - The sales of several core products, including injectable multivitamins, potassium chloride sustained-release tablets, and other key medications, have shown significant and stable growth during the reporting period [1] - Additional products such as sitagliptin and metformin sustained-release tablets, flurbiprofen ester injection, and injectable papaverine hydrochloride have contributed to incremental growth [1]